Resverlogix Corp
Resverlogix is a late-stage clinical biotechnology company founded in 2001, dedicated to improving the lives of patients with chronic illnesses through novel epigenetic therapeutics. The company's mission is to develop safe, epigenetic drugs that regulate gene expression to restore biological functions affected by serious diseases such as cardiovascular disease, chronic kidney disease, and neurodegeneration. Resverlogix aims to lead the future of drug development by providing innovative health solutions and advancing its lead compound, apabetalone, which is in late-stage clinical evaluation for high-risk cardiovascular disease and post COVID-19 conditions.
Industries
Nr. of Employees
small (1-50)
Resverlogix Corp
300, 4820 Richard Road SW, Calgary, AB, CANADA, T3E 6L1
Patents
Compositions and therapeutic methods for the treatment of complement-associated diseases
US-10772894-B2
View DetailsCrystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
US-10752595-B2
View DetailsCompositions and therapeutic methods for the treatment of complement-associated diseases
US-10111885-B2
View Details
Compositions and therapeutic methods for the treatment of complement-associated diseases
US-10772894-B2
View DetailsCrystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
US-10752595-B2
View DetailsCompositions and therapeutic methods for the treatment of complement-associated diseases
US-10111885-B2
View DetailsProducts
Selective BET inhibitor small‑molecule epigenetic therapeutic (oral)
An orally administered, selective small-molecule inhibitor of BET proteins in late-stage clinical development intended to modulate disease-associated gene expression for treatment of high‑risk cardiovascular disease and other chronic conditions (including post‑COVID conditions, chronic kidney disease, pulmonary arterial hypertension and neurodegenerative indications under study).
BETonMACE Phase 3 clinical trial (global)
A global Phase 3 clinical trial evaluating a selective BET inhibitor for reduction of major adverse cardiac events (MACE) and hospitalizations for heart failure in high‑risk patients with type 2 diabetes and coronary artery disease; includes pre‑specified cognitive and biomarker subanalyses.
Selective BET inhibitor small‑molecule epigenetic therapeutic (oral)
An orally administered, selective small-molecule inhibitor of BET proteins in late-stage clinical development intended to modulate disease-associated gene expression for treatment of high‑risk cardiovascular disease and other chronic conditions (including post‑COVID conditions, chronic kidney disease, pulmonary arterial hypertension and neurodegenerative indications under study).
BETonMACE Phase 3 clinical trial (global)
A global Phase 3 clinical trial evaluating a selective BET inhibitor for reduction of major adverse cardiac events (MACE) and hospitalizations for heart failure in high‑risk patients with type 2 diabetes and coronary artery disease; includes pre‑specified cognitive and biomarker subanalyses.
Services
Partnership-based commercialization support including market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, patient services, health economics and outcomes research, and compliance, augmented by data and predictive analytics.
Protocol development, steering committee support, clinical operations for Phase 2/3 and Phase 3 studies, adjudication processes and collaboration with investigator sites for multicenter trials.
Partnership-based commercialization support including market access, agency services, clinical and commercial field teams, medical science liaisons, channel management, patient services, health economics and outcomes research, and compliance, augmented by data and predictive analytics.
Protocol development, steering committee support, clinical operations for Phase 2/3 and Phase 3 studies, adjudication processes and collaboration with investigator sites for multicenter trials.
Expertise Areas
- Epigenetic therapeutics development (BET inhibition)
- Clinical trial management and global Phase 2/3 execution
- Cardiovascular outcomes research
- Pharmacology, toxicology and DMPK
Key Technologies
- BET (bromodomain) inhibition / epigenetic modulation
- Proteomics and biomarker assays
- Preclinical animal models
- Pharmacokinetics and DMPK studies